Results of a phase I trial of ganitumab plus dasatinib in patients with rhabdomyosarcoma (RMS). This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — A single infusion of letetresgene autoleucel demonstrated antitumor activity among patients with ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Afamitresgene autoleucel (afami-cel) induced responses in a third of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS), according to results of the phase II SPEARHEAD-1 ...
Interim analysis of pivotal IGNYTE-ESO trial demonstrates 40% response rate in people with synovial sarcoma or myxoid/ round cell liposarcoma Company will lay out plans for its cell therapy sarcoma ...
First-in-human Phase I study of NY-ESO-1 TCR/IL-15 NK for advanced synovial sarcoma and myxoid/round cell liposarcoma anticipated to commence Q3 2023 University of Texas M. D. Anderson Cancer Center ...
An expert writes about his experience as a sarcoma medical oncologist and how the field may progress with several therapies in the pipeline. As a sarcoma medical oncologist, the No. 1 question I am ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results